Inborn Errors of Mitochondrial Fatty Acid Oxidation: Overview from a Clinical Perspective
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Mitochondrial fatty acid β-oxidation (mFAO), which is the major pathway for the degradation of fatty acids and is critical for maintaining energy homeostasis in the human body, consists of carnitine transport, the carnitine shuttle, and fatty acid β-oxidation. Inherited metabolic defects of mFAO result in more than 15 distinct mFAO disorders (mFAODs) with varying clinical manifestations. The common elements of the clinical presentation of mFAODs are hypoketotic hypoglycemia, (cardio)myopathy, arrhythmia, and rhabdomyolysis, indicating the importance of FAO during fasting or stressful situations. The management of all mFAODs includes avoidance of fasting, aggressive treatment during illness, and supplementation of carnitine or appropriate nutritional support, if necessary. Through the introduction of newborn screening using tandem mass spectrometry, early identification of mFAODs became feasible, leading to an early initiation of treatment with improved outcomes. However, many unmet needs remain with regard to the long-term management of patients with mFAODs.
Abstract
Mitochondrial fatty acid β-oxidation (mFAO), which is the major pathway for the degradation of fatty acids and is critical for maintaining energy homeostasis in the human body, consists of carnitine transport, the carnitine shuttle, and fatty acid β-oxidation. Inherited metabolic defects of mFAO result in more than 15 distinct mFAO disorders (mFAODs) with varying clinical manifestations. The common elements of the clinical presentation of mFAODs are hypoketotic hypoglycemia, (cardio)myopathy, arrhythmia, and rhabdomyolysis, indicating the importance of FAO during fasting or stressful situations. The management of all mFAODs includes avoidance of fasting, aggressive treatment during illness, and supplementation of carnitine or appropriate nutritional support, if necessary. Through the introduction of newborn screening using tandem mass spectrometry, early identification of mFAODs became feasible, leading to an early initiation of treatment with improved outcomes. However, many unmet needs remain with regard to the long-term management of patients with mFAODs.
참고문헌 (13)
- Merritt JL 2nd, "Fatty acid oxidation disorders", Ann Transl Med, 6, pp.473~486 (2018)
- Houten SM, "The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders", Annu Rev Physiol, 78, pp.23~44 (2016)
- Houten SM, "A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation", J Inherit Metab Dis, 33, pp.469~477 (2010)
- Olpin SE, "Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability", J Inherit Metab Dis, 36, pp.645~658 (2013)
- Goetzman ES, "Advances in the understanding and treatment of mitochondrial fatty acid oxidation disorders", Curr Genet Med Rep, 5, pp.132~142 (2017)
- Zhu M, "Riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency in 13 cases, and a literature review in mainland Chinese patients", J Hum Genet, 59, pp.256~261 (2014)
- Yıldız Y, "Determinants of riboflavin responsiveness in multiple acyl-CoA dehydrogenase deficiency", Pediatr Neurol, 99, pp.69~75 (2019)
- Lindner M, "Newborn screening for disorders of fatty-acid oxidation : experience and recommendations from an expert meeting", J Inherit Metab Dis, 33, pp.521~526 (2010)
- Shibata N, "Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries : Selective screening vs. expanded newborn screening", Mol Genet Metab Rep, 16, pp.5~10 (2018)
- Yoon HR, "Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea : a three-year report", Clin Chim Acta, 354, pp.167~180 (2005)
- Bleeker JC, "Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes", J Inherit Metab Dis, 42, pp.414~423 (2019)
- Yusupov R, "Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency(MCADD)despite newborn screening", Mol Genet Metab, 101, pp.33~39 (2010)
- Kang E, "Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening", BMC Pediatr, 18, pp.103~109 (2018)